The 17 most recent market catalysts affecting $NKTR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 13, 2026
Corporate Catalyst
Bearish
Impact 65
Wedbush Cuts Price Target on Nektar Therapeutics to $40 From $50
Wedbush's decision to cut Nektar Therapeutics' price target from $50 to $40, while keeping a Neutral rating, stems directly from the company's Q3 2026 financial performance. The re…
Nov 12, 2026
Corporate Catalyst
Neutral
Impact 75
Nektar Therapeutics Announces Third Quarter 2026 Financial Results
Nektar Therapeutics released its Q3 2026 financial results and a business update on its clinical-stage pipeline. This is a standard quarterly earnings report, which is a significan…
Nov 2, 2026
Corporate Catalyst
Neutral
Impact 65
HC Wainwright & Co. Initiates Coverage of Nkarta with Buy Rating
HC Wainwright & Co. initiated coverage on Nkarta, Inc. with a 'Buy' rating and a $12.00 price target. This is a positive development for Nkarta as it signifies increased analyst at…
Oct 12, 2026
Corporate Catalyst
Neutral
Impact 55
UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53
UBS analyst Alice Nettleton has initiated coverage on Nektar Therapeutics with a 'Neutral' rating and a $53 price target. This event is significant as it introduces a new instituti…
Oct 12, 2026
Corporate Catalyst
Neutral
Impact 65
Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130
Leerink Partners analyst Will Soghikian initiated coverage on Nektar Therapeutics (NKTR) with an 'Outperform' rating and a significant price target of $130. This event is a positiv…
Oct 9, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
BTIG analyst Julian Harrison has reaffirmed a 'Buy' rating and a $178 price target for Nektar Therapeutics. This action signals that the analyst's investment thesis for NKTR remain…
Oct 2, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target
HC Wainwright & Co. analyst Arthur He reiterated a 'Buy' rating and maintained an $185 price target for Nektar Therapeutics. This action signals continued confidence from a promine…
Oct 1, 2026
Corporate Catalyst
Bearish
Impact 85
Nektar Therapeutics shares are trading lower after the company announced 52-week data from its Phase 2b REZOLVE-AA study in patients with severe-to-very-severe alopecia areata that may not sufficiently robust for investors. Also, investors may be trimming positions after a 15-month rally with Phase 3 results expected next year.
The primary driver of the stock's decline is the underwhelming 52-week data from the REZOLVE-AA study. While not a complete failure, the data's perceived lack of robustness is a si…
Oct 1, 2026
Corporate Catalyst
Neutral
Impact 55
Nektar Therapeutics Presents Data On Rezpegaldesleukin From Its Phase 2b REZOLVE-A, Phase 2b REZOLVE-AD Trials At European Academy Of Dermatology And Venereology
Nektar Therapeutics is presenting long-term data for rezpegaldesleukin from its Phase 2b REZOLVE-AA and REZOLVE-AD studies at the EADV Congress in 2026. This announcement itself is…
Sep 28, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
This 8-K filing discloses that BTIG analyst Julian Harrison has reiterated a 'Buy' rating on Nektar Therapeutics (NKTR) and maintained a $178 price target. This action signifies th…
Sep 25, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
This filing indicates that BTIG analyst Julian Harrison has reaffirmed their 'Buy' rating on Nektar Therapeutics (NKTR) and maintained a $178 price target. This is a routine analys…
Sep 16, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
This 8-K filing discloses that BTIG analyst Julian Harrison has reiterated a 'Buy' rating for Nektar Therapeutics and maintained a $178 price target. This action signals continued …
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
This filing indicates that BTIG analyst Julian Harrison has reaffirmed their 'Buy' rating and $178 price target for Nektar Therapeutics. This is a reiteration, meaning the analyst'…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 65
Nektar Therapeutics Enters Quiet Period Beginning September 8 Until Public Announcement Of Data From 24-Week Off Treatment Follow-Up Period Of Phase 2b REZOLVE-AA Study Of Rezpegaldesleukin In Patients With Alopecia Areata
Nektar Therapeutics has entered a quiet period, effective September 8th, until the public announcement of data from the 24-week off-treatment follow-up period of its Phase 2b REZOL…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 85
Nektar Therapeutics Announces Publication Of Peer-Reviewed Data From 16-Week Induction Period Of REZOLVE-AD, Phase 2b Study Evaluating Rezpegaldesleukin In Adults With Atopic Dermatitis
Nektar Therapeutics has published peer-reviewed data from the 16-week induction period of its Phase 2b REZOLVE-AD study for rezpegaldesleukin in atopic dermatitis. The key takeaway…
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 55
JP Morgan Reinstates Neutral on Nektar Therapeutics, Announces $65 Price Target
JP Morgan's reinstatement of coverage on Nektar Therapeutics with a 'Neutral' rating and a $65 price target provides a fresh perspective from a major investment bank. This action i…
Jul 22, 2026
Corporate Catalyst
Neutral
Impact 65
Canaccord Genuity Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $153
Canaccord Genuity's initiation of coverage on Nektar Therapeutics with a 'Buy' rating and a $153 price target is a positive development for the company. Analyst coverage, especiall…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.